NASDAQ:CELG - Nasdaq -
108.24
+0.11 (+0.1%)
The current stock price of CELG is 108.24 null. In the past month the price increased by 3.1%. In the past year, price increased by 62.4%.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.
CELGENE CORP
86 MORRIS AVENUE
SUMMIT NJ 07901
CEO: Mark J. Alles
Phone: 908-673-9000
The current stock price of CELG is 108.24 null. The price increased by 0.1% in the last trading session.
The exchange symbol of CELGENE CORP is CELG and it is listed on the Nasdaq exchange.
CELG stock is listed on the Nasdaq exchange.
CELGENE CORP (CELG) has a market capitalization of 77.04B null. This makes CELG a Large Cap stock.
CELGENE CORP (CELG) has a support level at 103.73 and a resistance level at 109.42. Check the full technical report for a detailed analysis of CELG support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CELG does not pay a dividend.
The PE ratio for CELGENE CORP (CELG) is 11. This is based on the reported non-GAAP earnings per share of 9.84 and the current share price of 108.24 null. Check the full fundamental report for a full analysis of the valuation metrics for CELG.
ChartMill assigns a technical rating of 10 / 10 to CELG. When comparing the yearly performance of all stocks, CELG is one of the better performing stocks in the market, outperforming 94.89% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to CELG. While CELG belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months CELG reported a non-GAAP Earnings per Share(EPS) of 9.84. The EPS increased by 33.51% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 34.62% | ||
ROA | 14.22% | ||
ROE | 48.65% | ||
Debt/Equity | 1.51 |
ChartMill assigns a Buy % Consensus number of 60% to CELG. The Buy consensus is the average rating of analysts ratings from 17 analysts.